See the DrugPatentWatch profile for Copiktra
What happened with Copiktra (duvelisib) indications in 2022–2023?
Copiktra (duvelisib) had an FDA-required step-down in its approved uses after safety findings. In 2022, the FDA approved label changes that removed the indication for certain patients with relapsed or refractory CLL/SLL and limited remaining uses to settings tied to specific guideline-recommended therapies and/or specific disease states. The FDA’s action was based on concerns from confirmatory trial data about overall survival and an increased risk profile for serious adverse events, including infections and other complications associated with idelalisib-class PI3K inhibitors.
In 2023, the key development for “withdrawn indication” searches is that the FDA label continued to reflect the narrowed approvals from the earlier 2022 label revision, rather than a return to the removed uses. Searches for 2022 vs. 2023 typically reflect that the label updates and public FDA communications were concentrated around 2022, with ongoing prescribing and payer/physician adjustments continuing into 2023.
Which Copiktra indication was withdrawn or removed?
The removed indication was the one that had supported broader use in relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), following the safety/benefit concerns that led to the FDA’s label restriction. In practice, this meant oncologists could no longer use Copiktra for the previously broader post–standard-therapy CLL/SLL population reflected in the earlier label.
Why did the FDA restrict (and effectively withdraw) those indications?
The FDA’s label restriction followed review of confirmatory and safety data for duvelisib in CLL/SLL. The key themes were an unfavorable risk-benefit balance and serious toxicities that were considered clinically significant, leading the FDA to require narrowing of the approved use.
Where did FDA make the changes publicly (what to look up)?
For the most accurate wording (exact language of the withdrawn indication), look up:
- The FDA label history for duvelisib/Copiktra on FDA’s prescribing information page and label version chronology
- FDA communications tied to PI3K inhibitor class safety actions and the Copiktra label update around 2022
- The manufacturer’s updated “Highlights of Prescribing Information” and “Indications and Usage” sections in the specific label revision effective during 2022
If you paste the exact indication text you’re trying to verify (for example, the CLL/SLL subgroup language from your source), I can help map it to the corresponding FDA label revision and the timeframe (2022 vs. 2023).
---
Sources
I don’t have the specific FDA label/withdrawal documents available in the provided materials, so I can’t cite them reliably here. If you share a link (or the exact FDA label version/date or the “Indications and Usage” wording from your document), I’ll pinpoint the withdrawn language and summarize what the FDA changed in 2022–2023 with exact citations.